10x Genomics (TXG) Receivables (2018 - 2026)

10x Genomics has disclosed Receivables across 9 years of filings, most recently posting $50.6 million for Q2 2026.

• In Q2 2026, Receivables fell 57.48% year-over-year to $50.6 million; the TTM figure through Jun 2026 stood at $50.6 million (down 57.48% YoY), while the FY2025 annual figure was $82.5 million, down 6.75% from the prior year.
• Receivables came in at $50.6 million for Q2 2026 at 10x Genomics, up from $20.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $119.1 million in Q2 2025 to a low of $20.9 million in Q1 2026.
• Average Receivables over 5 years is $83.4 million, with a median of $85.6 million recorded in 2022.
• Year-over-year, Receivables soared 33.3% in 2022 and slumped 60.22% in 2026.
• Over 5 years, Receivables stood at $104.2 million in 2022, then increased by 10.19% to $114.8 million in 2023, then declined by 23.49% to $87.9 million in 2024, then fell by 6.11% to $82.5 million in 2025, then plunged by 38.63% to $50.6 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $50.6 million in Q2 2026, $20.9 million in Q1 2026, and $82.5 million in Q4 2025.